{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T19:59:00Z","timestamp":1780343940875,"version":"3.54.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T00:00:00Z","timestamp":1637971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T00:00:00Z","timestamp":1637971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"national natural science foundation of china","doi-asserted-by":"publisher","award":["81773282"],"award-info":[{"award-number":["81773282"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"national natural science foundation of china","doi-asserted-by":"publisher","award":["81972630"],"award-info":[{"award-number":["81972630"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cancer cachexia is a wasting disorder characterized by significant weight loss, and is attributed to skeletal muscle weakness. In the process of cancer development, microRNAs act as oncogenes or tumor suppressors. Moreover, they are implicated in muscle development and wasting. This study sought to explore the mechanisms and correlation between miR-29c and muscle wasting in lung cancer cachexia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data for expression analysis were retrieved from the Cancer Genome Atlas (TCGA) database. qRT-PCR analyses were performed to explore the expression levels of miR-29c and Leukemia Inhibitory Factor (LIF). Lewis lung carcinoma (LLC) cell line was used to establish a cachexia model to explore the functions of miR-29c and LIF in lung cancer cachexia. Furthermore, in vitro (in C2C12 myotubes) and in vivo (in LLC tumor-bearing mice) experiments were performed to explore the mechanisms of miR-29c and LIF in lung cachexia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Analysis of the lung cancer cachexia model showed that miR-29c was down-regulated, and its expression was negatively correlated with muscle catabolic activity. Overexpression of miR-29c mitigated the cachectic phenotype. Mechanistic studies showed that LIF was a direct target gene of miR-29c, and LIF was upregulated in vitro and in vivo. Analysis showed that LIF promoted muscle wasting through the JAK\/STAT and MAP-kinase pathways.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The findings indicated that miR-29c was negatively correlated with the cachectic phenotype, and the miR-29c-LIF axis is a potential therapeutic target for cancer cachexia.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12935-021-02332-w","type":"journal-article","created":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T09:02:41Z","timestamp":1638003761000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Downregulation of miR-29c promotes muscle wasting by modulating the activity of leukemia inhibitory factor in lung cancer cachexia"],"prefix":"10.1186","volume":"21","author":[{"given":"Kairu","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairong","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changfei","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daojia","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0924-5795","authenticated-orcid":false,"given":"Hongmei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,27]]},"reference":[{"issue":"11","key":"2332_CR1","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/nrc3829","volume":"14","author":"JM Argiles","year":"2014","unstructured":"Argiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer. 2014;14(11):754\u201362.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2332_CR2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489\u201395.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2332_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/nrd4467","volume":"14","author":"S Cohen","year":"2015","unstructured":"Cohen S, Nathan JA, Goldberg AL. Muscle wasting in disease: molecular mechanisms and promising therapies. Nat Rev Drug Discovery. 2015;14(1):58\u201374.","journal-title":"Nat Rev Drug Discovery"},{"issue":"4","key":"2332_CR4","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","volume":"142","author":"XL Zhou","year":"2010","unstructured":"Zhou XL, Wang JL, Lu J, Song YP, Kwak KS, Jiao QS, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 2010;142(4):531\u201343.","journal-title":"Cell"},{"key":"2332_CR5","doi-asserted-by":"crossref","unstructured":"Rausch V, Sala V, Penna F, Porporato PE, Ghigo A. Understanding the common mechanisms of heart and skeletal muscle wasting in cancer cachexia. Oncogenesis. 2021;10(1).","DOI":"10.1038\/s41389-020-00288-6"},{"issue":"2","key":"2332_CR6","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","volume":"16","author":"KCH Fearon","year":"2012","unstructured":"Fearon KCH, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012;16(2):153\u201366.","journal-title":"Cell Metab"},{"key":"2332_CR7","doi-asserted-by":"crossref","unstructured":"Chen R, Lei S, Jiang T, She YL, Shi HC. Regulation of skeletal muscle atrophy in cachexia by MicroRNAs and long non-coding RNAs. Front Cell Dev Biol. 2020;8.","DOI":"10.3389\/fcell.2020.577010"},{"issue":"7516","key":"2332_CR8","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature13528","volume":"513","author":"S Kir","year":"2014","unstructured":"Kir S, White JP, Kleiner S, Kazak L, Cohen P, Baracos VE, et al. Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature. 2014;513(7516):100.","journal-title":"Nature"},{"issue":"5","key":"2332_CR9","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41568-020-0251-4","volume":"20","author":"AK Biswas","year":"2020","unstructured":"Biswas AK, Acharyya S. Understanding cachexia in the context of metastatic progression. Nat Rev Cancer. 2020;20(5):274\u201384.","journal-title":"Nat Rev Cancer"},{"issue":"20","key":"2332_CR10","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1038\/emboj.2011.292","volume":"30","author":"GH Zhang","year":"2011","unstructured":"Zhang GH, Jin BW, Li YP. C\/EBP beta mediates tumour-induced ubiquitin ligase atrogin1\/MAFbx upregulation and muscle wasting. EMBO J. 2011;30(20):4323\u201335.","journal-title":"EMBO J"},{"issue":"1","key":"2332_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1096\/fj.10-164152","volume":"25","author":"A Doyle","year":"2011","unstructured":"Doyle A, Zhang GH, Fattah EAA, Eissa NT, Li YP. Toll-like receptor 4 mediates lipopolysaccharide-induced muscle catabolism via coordinate activation of ubiquitin-proteasome and autophagy-lysosome pathways. FASEB J. 2011;25(1):99\u2013110.","journal-title":"FASEB J"},{"issue":"2","key":"2332_CR12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nrclinonc.2012.209","volume":"10","author":"K Fearon","year":"2013","unstructured":"Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol. 2013;10(2):90\u20139.","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"2332_CR13","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1517\/13543784.2014.942729","volume":"23","author":"AMC Dingemans","year":"2014","unstructured":"Dingemans AMC, de Vos-Geelen J, Langen R, Schols AMW. Phase II drugs that are currently in development for the treatment of cachexia. Expert Opin Investig Drugs. 2014;23(12):1655\u201369.","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"2332_CR14","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","volume":"116","author":"DP Bartel","year":"2004","unstructured":"Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281\u201397.","journal-title":"Cell"},{"key":"2332_CR15","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.2147\/CMAR.S166308","volume":"10","author":"SX Yang","year":"2018","unstructured":"Yang SX, Sun ZQ, Zhou QB, Wang WW, Wang GX, Song JM, et al. MicroRNAs, long noncoding RNAs, and circular RNAs: potential tumor biomarkers and targets for colorectal cancer. Cancer Manage Res. 2018;10:2249\u201357.","journal-title":"Cancer Manage Res"},{"issue":"32","key":"2332_CR16","doi-asserted-by":"publisher","first-page":"21909","DOI":"10.1074\/jbc.M114.561845","volume":"289","author":"RJ Soares","year":"2014","unstructured":"Soares RJ, Cagnin S, Chemello F, Silvestrin M, Musaro A, De Pitta C, et al. Involvement of MicroRNAs in the regulation of muscle wasting during catabolic conditions. J Biol Chem. 2014;289(32):21909\u201325.","journal-title":"J Biol Chem"},{"key":"2332_CR17","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.omto.2018.12.011","volume":"12","author":"JJ Kwon","year":"2019","unstructured":"Kwon JJ, Factora TD, Dey S, Kota J. A systematic review of miR-29 in cancer. Mol Ther-Oncolytics. 2019;12:173\u201394.","journal-title":"Mol Ther-Oncolytics"},{"key":"2332_CR18","doi-asserted-by":"crossref","unstructured":"Sun DM, Tang BF, Li ZX, Guo HB, Cheng JL, Song PP, et al. MiR-29c reduces the cisplatin resistance of non-small cell lung cancer cells by negatively regulating the PI3K\/Akt pathway. Sci Rep. 2018;8.","DOI":"10.1038\/s41598-018-26381-w"},{"issue":"10","key":"2332_CR19","first-page":"2392","volume":"1853","author":"S Trehoux","year":"2015","unstructured":"Trehoux S, Lahdaoui F, Delpu Y, Renaud F, Leteurtre E, Torrisani J, et al. Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells. BBA-Mol Cell Res. 2015;1853(10):2392\u2013403.","journal-title":"BBA-Mol Cell Res"},{"issue":"7","key":"2332_CR20","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1158\/0008-5472.CAN-14-0787","volume":"75","author":"YX Wang","year":"2015","unstructured":"Wang YX, Liu CZ, Luo M, Zhang ZY, Gong JN, Li JJ, et al. Chemotherapy-induced miRNA-29c\/Catenin-delta signaling suppresses metastasis in gastric cancer. Can Res. 2015;75(7):1332\u201344.","journal-title":"Can Res"},{"issue":"5","key":"2332_CR21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccr.2008.10.006","volume":"14","author":"H Wang","year":"2008","unstructured":"Wang H, Garzon R, Sun H, Ladner KJ, Singh R, Dahlman J, et al. NF-kappa B-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell. 2008;14(5):369\u201381.","journal-title":"Cancer Cell"},{"key":"2332_CR22","doi-asserted-by":"crossref","unstructured":"Silva WJ, Graca FA, Cruz A, Silvestre JG, Labeit S, Miyabara EH, et al. miR-29c improves skeletal muscle mass and function throughout myocyte proliferation and differentiation and by repressing atrophy-related genes. Acta Physiol. 2019;226(4).","DOI":"10.1111\/apha.13278"},{"issue":"2","key":"2332_CR23","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1096\/fj.13-240580","volume":"28","author":"MJ Puppa","year":"2014","unstructured":"Puppa MJ, Gao S, Narsale AA, Carson JA. Skeletal muscle glycoprotein 130\u2019s role in Lewis lung carcinoma-induced cachexia. FASEB J. 2014;28(2):998\u20131009.","journal-title":"FASEB J"},{"issue":"1","key":"2332_CR24","doi-asserted-by":"publisher","first-page":"C101","DOI":"10.1152\/ajpcell.00344.2015","volume":"311","author":"R Sun","year":"2016","unstructured":"Sun R, Zhang S, Hu W, Lu X, Lou N, Yang Z, et al. Valproic acid attenuates skeletal muscle wasting by inhibiting C\/EBP beta-regulated atrogin1 expression in cancer cachexia. Am J Physiol Cell Physiol. 2016;311(1):C101\u201315.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"8","key":"2332_CR25","first-page":"1091","volume":"1864","author":"WJ Hu","year":"2019","unstructured":"Hu WJ, Ru ZY, Zhou YL, Xiao W, Sun RL, Zhang ST, et al. Lung cancer-derived extracellular vesicles induced myotube atrophy and adipocyte lipolysis via the extracellular IL-6-mediated STAT3 pathway. BBA-Mol Cell Biol L. 2019;1864(8):1091\u2013102.","journal-title":"BBA-Mol Cell Biol L"},{"issue":"11","key":"2332_CR26","doi-asserted-by":"publisher","first-page":"19280","DOI":"10.1002\/jcp.28607","volume":"234","author":"M Alizadeh","year":"2019","unstructured":"Alizadeh M, Safarzadeh A, Beyranvand F, Ahmadpour F, Hajiasgharzadeh K, Baghbanzadeh A, et al. The potential role of miR-29 in health and cancer diagnosis, prognosis, and therapy. J Cell Physiol. 2019;234(11):19280\u201397.","journal-title":"J Cell Physiol"},{"key":"2332_CR27","doi-asserted-by":"crossref","unstructured":"Sun CC, Li SJ, Li G, Hua RX, Zhou XH, Li DJ. Long intergenic noncoding RNA 00511 acts as an oncogene in non-small-cell lung cancer by binding to EZH2 and suppressing p57. Mol Ther-Nucleic Acids. 2016;5.","DOI":"10.1038\/mtna.2016.94"},{"issue":"19","key":"2332_CR28","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1007\/s00018-018-2877-x","volume":"75","author":"C Bica-Pop","year":"2018","unstructured":"Bica-Pop C, Cojocneanu-Petric R, Magdo L, Raduly L, Gulei D, Berindan-Neagoe I. Overview upon miR-21 in lung cancer: focus on NSCLC. Cell Mol Life Sci. 2018;75(19):3539\u201351.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"2332_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.biopha.2011.09.004","volume":"66","author":"W Gao","year":"2012","unstructured":"Gao W, Xu J, Liu L, Shen H, Zeng H, Shu Y. A systematic-analysis of predicted miR-21 targets identifies a signature for lung cancer. Biomed Pharmacother. 2012;66(1):21\u20138.","journal-title":"Biomed Pharmacother"},{"issue":"17","key":"2332_CR30","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1111\/1759-7714.14060","volume":"12","author":"JM Tang","year":"2021","unstructured":"Tang JM, Li X, Cheng TL, Wu J. miR-21-5p\/SMAD7 axis promotes the progress of lung cancer. Thoracic Cancer. 2021;12(17):2307\u201313.","journal-title":"Thoracic Cancer"},{"issue":"4","key":"2332_CR31","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/jcsm.12565","volume":"11","author":"PP Freire","year":"2020","unstructured":"Freire PP, Fernandez GJ, de Moraes D, Cury SS, Dal Pai-Silva M, Dos Reis PP, et al. The expression landscape of cachexia-inducing factors in human cancers. J Cachexia Sarcopenia Muscle. 2020;11(4):947\u201361.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"5","key":"2332_CR32","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.cytogfr.2015.07.001","volume":"26","author":"NA Nicola","year":"2015","unstructured":"Nicola NA, Babon JJ. Leukemia inhibitory factor (LIF). Cytokine Growth Factor Rev. 2015;26(5):533\u201344.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"8","key":"2332_CR33","doi-asserted-by":"publisher","first-page":"6207","DOI":"10.1021\/cr300362f","volume":"113","author":"HF Dong","year":"2013","unstructured":"Dong HF, Lei JP, Ding L, Wen YQ, Ju HX, Zhang XJ. MicroRNA: function, detection, and bioanalysis. Chem Rev. 2013;113(8):6207\u201333.","journal-title":"Chem Rev"},{"issue":"1","key":"2332_CR34","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.cell.2005.06.036","volume":"122","author":"CM Croce","year":"2005","unstructured":"Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell. 2005;122(1):6\u20137.","journal-title":"Cell"},{"issue":"2","key":"2332_CR35","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1053\/j.gastro.2007.05.022","volume":"133","author":"FY Meng","year":"2007","unstructured":"Meng FY, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133(2):647\u201358.","journal-title":"Gastroenterology"},{"issue":"17","key":"2332_CR36","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1056\/NEJMoa050995","volume":"353","author":"GA Calin","year":"2005","unstructured":"Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005;353(17):1793\u2013801.","journal-title":"N Engl J Med"},{"issue":"40","key":"2332_CR37","doi-asserted-by":"publisher","first-page":"15805","DOI":"10.1073\/pnas.0707628104","volume":"104","author":"M Fabbri","year":"2007","unstructured":"Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA. 2007;104(40):15805\u201310.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2332_CR38","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.bbrc.2017.03.110","volume":"486","author":"S Mahati","year":"2017","unstructured":"Mahati S, Xiao L, Yang Y, Mao R, Bao YX. miR-29a suppresses growth and migration of hepatocellular carcinoma by regulating CLDN1. Biochem Biophys Res Commun. 2017;486(3):732\u20137.","journal-title":"Biochem Biophys Res Commun"},{"issue":"13","key":"2332_CR39","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1002\/j.1460-2075.1987.tb02742.x","volume":"6","author":"DP Gearing","year":"1987","unstructured":"Gearing DP, Gough NM, King JA, Hilton DJ, Nicola NA, Simpson RJ, et al. Molecular cloning and expression of cDNA encoding a murine myeloid leukaemia inhibitory factor (LIF). EMBO J. 1987;6(13):3995\u20134002.","journal-title":"EMBO J"},{"key":"2332_CR40","doi-asserted-by":"publisher","first-page":"107754","DOI":"10.1016\/j.pharmthera.2020.107754","volume":"221","author":"C Zhang","year":"2021","unstructured":"Zhang C, Liu J, Wang J, Hu W, Feng Z. The emerging role of leukemia inhibitory factor in cancer and therapy. Pharmacol Ther. 2021;221:107754.","journal-title":"Pharmacol Ther"},{"key":"2332_CR41","doi-asserted-by":"crossref","unstructured":"Yu H, Yue X, Zhao Y, Li X, Wu L, Zhang C, et al. LIF negatively regulates tumour-suppressor p53 through Stat3\/ID1\/MDM2 in colorectal cancers. Nat Commun. 2014;5.","DOI":"10.1038\/ncomms6218"},{"issue":"2","key":"2332_CR42","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0022-510X(91)90045-9","volume":"101","author":"L Austin","year":"1991","unstructured":"Austin L, Burgess AW. Stimulation of myoblast proliferation in culture by leukaemia inhibitory factor and other cytokines. J Neurol Sci. 1991;101(2):193\u20137.","journal-title":"J Neurol Sci"},{"issue":"3","key":"2332_CR43","first-page":"187","volume":"1743","author":"C Jo","year":"2005","unstructured":"Jo C, Kim H, Jo I, Choi I, Jung SC, Kim J, et al. Leukemia inhibitory factor blocks early differentiation of skeletal muscle cells by activating ERK. BBA-Mol Cell Res. 2005;1743(3):187\u201397.","journal-title":"BBA-Mol Cell Res"},{"issue":"1\u20132","key":"2332_CR44","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/0022-510X(94)90211-9","volume":"123","author":"W Barnard","year":"1994","unstructured":"Barnard W, Bower J, Brown MA, Murphy M, Austin L. Leukemia inhibitory factor (LIF) infusion stimulates skeletal muscle regeneration after injury: injured muscle expresses lif mRNA. J Neurol Sci. 1994;123(1\u20132):108\u201313.","journal-title":"J Neurol Sci"},{"key":"2332_CR45","doi-asserted-by":"crossref","unstructured":"Donzelli S, Farneti A, Marucci L, Ganci F, Sacconi A, Strano S, et al. Non-coding RNAs as putative biomarkers of cancer-associated cachexia. Front Cell Dev Biol. 2020;8.","DOI":"10.3389\/fcell.2020.00257"},{"issue":"12","key":"2332_CR46","doi-asserted-by":"publisher","first-page":"4525","DOI":"10.1073\/pnas.1402714111","volume":"111","author":"WA He","year":"2014","unstructured":"He WA, Calore F, Londhe P, Canella A, Guttridge DC, Croce CM. Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proc Natl Acad Sci USA. 2014;111(12):4525\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2332_CR47","doi-asserted-by":"crossref","unstructured":"Powrozek T, Mlak R, Brzozowska A, Mazurek M, Golebiowski P, Malecka-Massalska T. miRNA-130a significantly improves accuracy of SGA nutritional assessment tool in prediction of malnutrition and cachexia in radiotherapy-treated head and neck cancer patients. Cancers. 2018;10(9).","DOI":"10.3390\/cancers10090294"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-021-02332-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-021-02332-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-021-02332-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T21:21:59Z","timestamp":1638048119000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-021-02332-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,27]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2332"],"URL":"https:\/\/doi.org\/10.1186\/s12935-021-02332-w","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,27]]},"assertion":[{"value":"18 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for use of animals in the current study was obtained from the Institutional Animal Care and Use Committee of Tongji Medical College, Huazhong University of Science & Technology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"627"}}